Literature DB >> 26077226

Lynch syndrome and cervical cancer.

Yoland C Antill1, James G Dowty2, Aung Ko Win2, Tina Thompson3, Michael D Walsh4, Margaret C Cummings5, Steven Gallinger6, Noralane M Lindor7, Loïc Le Marchand8, John L Hopper2,9, Polly A Newcomb10,11, Robert W Haile12, James Church13, Katherine M Tucker14, Daniel D Buchanan2,15, Joanne P Young16,17,18, Ingrid M Winship19,20, Mark A Jenkins2.   

Abstract

Carriers of germline mutations in DNA mismatch repair (MMR) genes are at increased risk of several cancers including colorectal and gynecologic cancers (Lynch syndrome). There is no substantial evidence that these mutations are associated with an increased risk of cervical cancer. A total of 369 families with at least one carrier of a mutation in a MMR gene (133 MLH1, 174 MSH2, 35 MSH6 and 27 PMS2) were ascertained via population cancer registries or via family cancer clinics in Australia, New Zealand, Canada, and USA. Personal and family histories of cancer were obtained from participant interviews. Modified segregation analysis was used to estimate the hazard ratio (incidence rates for carriers relative to those for the general population), and age-specific cumulative risks of cervical cancer for carriers. A total of 65 cases of cervical cancer were reported (including 10 verified by pathology reports). The estimated incidence was 5.6 fold (95% CI: 2.3-13.8; p = 0.001) higher for carriers than for the general population with a corresponding cumulative risk to 80 years of 4.5% (95% CI: 1.9-10.7%) compared with 0.8% for the general population. The mean age at diagnosis was 43.1 years (95% CI: 40.0-46.2), 3.9 years younger than the reported USA population mean of 47.0 years (p = 0.02). Women with MMR gene mutations were found to have an increased risk of cervical cancer. Due to limited pathology verification we cannot be certain that a proportion of these cases were not lower uterine segment endometrial cancers involving the endocervix, a recognized cancer of Lynch syndrome.
© 2015 UICC.

Entities:  

Keywords:  Lynch syndrome; cervical cancer; mismatch repair

Mesh:

Year:  2015        PMID: 26077226      PMCID: PMC4573262          DOI: 10.1002/ijc.29641

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  21 in total

1.  Cervical adenocarcinoma in a patient with Lynch syndrome, Muir-Torre variant.

Authors:  Navya Nair; John P Curtin; Khushbakhat Mittal; Karen L Hiotis
Journal:  J Clin Oncol       Date:  2011-11-28       Impact factor: 44.544

2.  Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.

Authors:  Valérie Bonadona; Bernard Bonaïti; Sylviane Olschwang; Sophie Grandjouan; Laetitia Huiart; Michel Longy; Rosine Guimbaud; Bruno Buecher; Yves-Jean Bignon; Olivier Caron; Chrystelle Colas; Catherine Noguès; Sophie Lejeune-Dumoulin; Laurence Olivier-Faivre; Florence Polycarpe-Osaer; Tan Dat Nguyen; Françoise Desseigne; Jean-Christophe Saurin; Pascaline Berthet; Dominique Leroux; Jacqueline Duffour; Sylvie Manouvrier; Thierry Frébourg; Hagay Sobol; Christine Lasset; Catherine Bonaïti-Pellié
Journal:  JAMA       Date:  2011-06-08       Impact factor: 56.272

3.  Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome.

Authors:  Aung Ko Win; Noralane M Lindor; Joanne P Young; Finlay A Macrae; Graeme P Young; Elizabeth Williamson; Susan Parry; Jack Goldblatt; Lara Lipton; Ingrid Winship; Barbara Leggett; Katherine M Tucker; Graham G Giles; Daniel D Buchanan; Mark Clendenning; Christophe Rosty; Julie Arnold; A Joan Levine; Robert W Haile; Steven Gallinger; Loïc Le Marchand; Polly A Newcomb; John L Hopper; Mark A Jenkins
Journal:  J Natl Cancer Inst       Date:  2012-08-28       Impact factor: 13.506

4.  Hereditary nonpolyposis colorectal cancer with gynecologic malignancies: report of two families in Taiwan.

Authors:  C H Chen; R L Huang; M S Yu; L J Wong; T F Chao; T Y Chu
Journal:  J Formos Med Assoc       Date:  2001-04       Impact factor: 3.282

5.  Cancer risks for MLH1 and MSH2 mutation carriers.

Authors:  James G Dowty; Aung K Win; Daniel D Buchanan; Noralane M Lindor; Finlay A Macrae; Mark Clendenning; Yoland C Antill; Stephen N Thibodeau; Graham Casey; Steve Gallinger; Loic Le Marchand; Polly A Newcomb; Robert W Haile; Graeme P Young; Paul A James; Graham G Giles; Shanaka R Gunawardena; Barbara A Leggett; Michael Gattas; Alex Boussioutas; Dennis J Ahnen; John A Baron; Susan Parry; Jack Goldblatt; Joanne P Young; John L Hopper; Mark A Jenkins
Journal:  Hum Mutat       Date:  2013-03       Impact factor: 4.878

Review 6.  Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis.

Authors:  Shae Ryan; Mark A Jenkins; Aung Ko Win
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-01-14       Impact factor: 4.254

7.  Laryngeal carcinoma in a Lynch syndrome II kindred.

Authors:  H T Lynch; M Kriegler; T A Christiansen; T Smyrk; J F Lynch; P Watson
Journal:  Cancer       Date:  1988-09-01       Impact factor: 6.860

8.  Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.

Authors:  Murray Joseph Casey; Chhanda Bewtra; Henry T Lynch; Carrie Snyder; Mark Stacy; Patrice Watson
Journal:  Fam Cancer       Date:  2013-12       Impact factor: 2.375

Review 9.  Risk of breast cancer in Lynch syndrome: a systematic review.

Authors:  Aung Ko Win; Noralane M Lindor; Mark A Jenkins
Journal:  Breast Cancer Res       Date:  2013-03-19       Impact factor: 6.466

10.  Relationship of lower uterine segment cancer with Lynch syndrome: a novel case with an hMLH1 germline mutation.

Authors:  Kenta Masuda; Kouji Banno; Akira Hirasawa; Megumi Yanokura; Kosuke Tsuji; Yusuke Kobayashi; Iori Kisu; Arisa Ueki; Hiroyuki Nomura; Eiichiro Tominaga; Nobuyuki Susumu; Daisuke Aoki
Journal:  Oncol Rep       Date:  2012-08-31       Impact factor: 3.906

View more
  5 in total

1.  Tumor Evolution in a Patient with Recurrent Endometrial Cancer and Synchronous Neuroendocrine Cancer and Response to Checkpoint Inhibitor Treatment.

Authors:  Nikolaos A Trikalinos; Deyali Chatterjee; Kyle Winter; Matthew Powell; Motoyo Yano
Journal:  Oncologist       Date:  2020-10-03       Impact factor: 5.837

Review 2.  The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications.

Authors:  Zheng Hu; Ding Ma
Journal:  Cancer Med       Date:  2018-09-14       Impact factor: 4.452

3.  Modelling Chlamydia and HPV co-infection in patient-derived ectocervix organoids reveals distinct cellular reprogramming.

Authors:  Stefanie Koster; Rajendra Kumar Gurumurthy; Naveen Kumar; Pon Ganish Prakash; Jayabhuvaneshwari Dhanraj; Sofia Bayer; Hilmar Berger; Shilpa Mary Kurian; Marina Drabkina; Hans-Joachim Mollenkopf; Christian Goosmann; Volker Brinkmann; Zachary Nagel; Mandy Mangler; Thomas F Meyer; Cindrilla Chumduri
Journal:  Nat Commun       Date:  2022-02-24       Impact factor: 17.694

4.  Genomic, transcriptomic, and viral integration profiles associated with recurrent/metastatic progression in high-risk human papillomavirus cervical carcinomas.

Authors:  Jing Jing Liu; Jung Yoon Ho; Jung Eum Lee; Soo Young Hur; Jinseon Yoo; Kyu Ryung Kim; Daeun Ryu; Tae Min Kim; Youn Jin Choi
Journal:  Cancer Med       Date:  2020-10-05       Impact factor: 4.452

Review 5.  Screening and identification of Lynch syndrome: a systematic review of the frequency of Lynch syndrome-associated clinicopathologic and molecular characteristics in Lynch syndrome gynecologic cancers.

Authors:  Zihui Yang; Xinyu Liu; Xi Yang; Qin-Ping Liao
Journal:  Transl Cancer Res       Date:  2021-10       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.